Biologics Witness Surge in Demand Owing to Rising Prevalence of Chronic Diseases

Biologics refer to medications derived from living organisms that are used to prevent and treat various chronic diseases. Biologics such as vaccines, blood components, allergenics, somatic cells, gene therapies, tissues, and recombinant therapeutic proteins have revolutionized the treatment of cancer, autoimmune disorders, infectious diseases, and other chronic conditions. The global biologics market has witnessed remarkable growth in recent years due to rising prevalence of chronic diseases worldwide. Increasing research for precision medicine and developing antibody-drug conjugates have further expanded biologics applications.

The global biologics Market is estimated to be valued at US$ 401.96 Bn in 2023 and is expected to exhibit a CAGR of 8.2% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Dynamics:
The rising prevalence of chronic diseases is one of the major drivers fueling the growth of the global biologics market. Chronic diseases requiring long-term biologics therapy such as diabetes, cancer, cardiovascular diseases, and autoimmune disorders are becoming highly prevalent worldwide. Furthermore, rapid approval of novel biologics and biologics biosimilars by regulatory authorities is expected to boost market growth over the forecast period. Continuous drug innovations and increasing uptake of specialty biologics drugs owing to their high efficacy will further accelerate the demand for biologics in the coming years.

SWOT Analysis
Strength:
- Biologics are highly targeted therapies which bind to specific proteins or receptors responsible for disease development. This provides strong treatment efficacy and fewer side effects.
- Research and development in biopharmaceuticals has grown significantly in the past decade leading to a robust product pipeline across various therapeutic areas like oncology, immunology and others.
- Strong patent and regulatory protection ensure market exclusivity and high returns on investment for developers of innovative biologics.

Weakness:
- Biologics are much more expensive to manufacture than small molecule drugs due to complex production processes requiring specialized infrastructure and highly skilled workforce.
- Higher costs are often a barrier to patients access and overall adoption across developing regions with budget constraints.

Opportunity:
- Rising healthcare expenditure in emerging economies will boost demand for premium therapies like biologics for previously untreated patient populations.
- Increasing prevalence of chronic non-communicable diseases globally provides a sizeable patient pool for development of novel biologic drugs targeting conditions like cancer, diabetes and autoimmune disorders.

Threats:
- Biosimilars pose significant pricing pressure on originator biologics facing patent expiration. This threat increases over time with wider acceptance and uptake of lower cost biosimilars.
- Stringent regulatory pathways can delay market launch and commercialization of new biologic drugs increasing costs related to prolonged development timelines.

Key Takeaways
The Global Biologics Market Size is expected to witness high growth over the forecast period supported by robust R&D investments in biopharmaceuticals and strong demand for specialized biologic treatments.

Regional Analysis: The Asia Pacific region is expected to offer high growth opportunities for biologics manufacturers given rising healthcare spending, availability of lower-cost biosimilars and presence of late-stage clinical trial hubs. China, Japan and South Korea are major manufacturing and consumer markets in the region supported by their large population bases and growing disease burden.

Key players operating in the biologics market are Advanced Accelerator Applications (AAA), Amgen, Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd, Johnson & Johnson, Merck & Co., Novartis AG, Pfizer Inc and Sanofi. These companies are focused on expanding their product portfolios through acquisitions and in-licensing deals given the high entry barriers of biologics development. Regional and global expansion into high-growth emerging markets is also a key focus.

Get more insights on this topic:
https://www.rapidwebwire.com/biologics-market-demand/